Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00820898. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial is studying the side effects of gemcitabine and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Study identification
- NCT ID
- NCT00820898
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 24 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2009 (Type not available)
- Primary completion
- Jan 2011 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 29, 2017
Started 2009
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hartford Hospital | Hartford | Connecticut | 06102 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Decatur Memorial Hospital | Decatur | Illinois | 62526 | — |
| Memorial Medical Center | Springfield | Illinois | 62781-0001 | — |
| Saint Vincent Hospital and Health Services | Indianapolis | Indiana | 46260 | — |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Maine Medical Center-Bramhall Campus | Portland | Maine | 04102 | — |
| Cooper Hospital University Medical Center | Camden | New Jersey | 08103 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Riverside Methodist Hospital | Columbus | Ohio | 43214 | — |
| Lake University Ireland Cancer Center | Mentor | Ohio | 44060 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Tulsa Cancer Institute | Tulsa | Oklahoma | 74146 | — |
| Abington Memorial Hospital | Abington | Pennsylvania | 19001 | — |
| Gynecologic Oncology Group | Philadelphia | Pennsylvania | 19103 | — |
| Women and Infants Hospital | Providence | Rhode Island | 02905 | — |
| Zale Lipshy University Hospital | Dallas | Texas | 75235 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00820898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 29, 2017 · Synced Nov 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.